20P - Discovery of novel 2beta-hydroxybetulinic acid 3beta-oliate via NF-_B pathway in Diethylnitrosamine induced Hepatocellular carcinoma in rats (20P)

Date 18 November 2017
Event ESMO Asia 2017 Congress
Session Poster lunch
Topics Basic Science
Presenter Danish Ahmed
Citation Annals of Oncology (2017) 28 (suppl_10): x1-x6. 10.1093/annonc/mdx652
Authors D. Ahmed1, M. Sharma2
  • 1Department Of Pharmaceutical Sciences, Sam Higginbottom Institute of Agriculture, Technology & Sciences (SHIATS), 211007 - Allahabad/IN
  • 2Dept. Of Pharmacology, Jamia Hamdard, 110019 - New Delhi/IN



Hepatocellular carcinoma (HCC) is the one of the major health problem in the world, is a leading cause of cancer related mortality. NF-kB pathways is considered as the singling pathway which activates the various cellular function including cell expansion, survival, proliferation and vesicular transport and found frequently dysregulated pathway in HCC. Consequently, natural product based inhibitors play a significant role in the NF-kB pathway and extensively scrutinized in the targeting the cancer in recent years. Present study was aimed to scrutinize the effect of 2beta-hydroxybetulinic acid 3beta-oliate (HBO) as NF-kB inhibitors for hepatic cancer.


Swiss albino Wistar rats (48) were divided into four groups. Diethylnitrosamine (DEN) (200 mg/kg) dose was used for induction the HCC in rats and treated with the HBO for 22 weeks. Pro-inflammatory cytokines including IL-6, TNF-α, IL-1β and NF-κB expression were estimated, respectively. Docking analysis was also performed with NF-kB (PDB:1NFK) to explicate imperative structural residues essential for bioactivity.


HBO significantly (p 


Collectively, we may conclude that HBO has shown excellent activity towards down-regulation of HCC via inhibition of NF-kB pathways supported by molecular docking research analysis. Therefore, HBO could be a potential candidate for hepatic cellular carcinoma.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.